Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2020
Principal Business: Development of regenerative cell therapy product candidates, including PLX-PAD, PLX-R18, and PLX cells for COVID-19 complications.
Key Financial Metrics and Liquidity
- Cash Position: Approximately $44 million as of April 30, 2020 (up from approximately $17 million as of December 31, 2019).
- Debt Financing: Entered into a Finance Contract with the European Investment Bank (EIB) for a loan of up to €50 million.
- Projected Liquidity: Assuming full receipt of the loan, total cash is expected to reach approximately $100 million, funding operations for the next 3 years.
- Revenue/Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
Material Changes and New Obligations
European Investment Bank Loan Agreement
On April 30, 2020, the Company and its subsidiaries entered into a loan agreement with the EIB for €50 million, payable in three tranches subject to clinical, regulatory, and scale-up milestones:
- Tranche 1: €20 million (0% fixed interest; 4% deferred interest).
- Tranche 2: €18 million (1.00% fixed interest; 3% deferred interest).
- Tranche 3: €12 million (1.00% fixed interest; 2% deferred interest).
Repayment Terms: Tranches 1 and 2 are due in a single installment five years after disbursement. Tranche 3 is due in two equal installments starting four years after disbursement.
Royalty Obligations: The Bank is entitled to royalty payments on consolidated revenues from fiscal year 2024 through 2030, ranging from 0.2% to 2.3% depending on revenue tiers ($350M and $500M thresholds).
Use of Proceeds: Funds are restricted to the development of PLX-PAD, PLX-R18, and PLX cells for COVID-19 (capped at €10 million unless compassionate use studies show positive results).
Outlook, Management Commentary, and Risks
Clinical Development Updates
- COVID-19: Filed an Investigational New Drug (IND) application with the FDA and Clinical Trial Authorization in Europe (Germany and Italy). Aims to commence Phase II studies upon regulatory clearance.
- Critical Limb Ischemia (CLI) Phase III: Over 80% enrolled. Enrollment slowed in April 2020 due to COVID-19. Interim top-line results delayed to the beginning of Q4 2020.
- Hip Fracture Phase III: Over 60% enrolled. Enrollment slowed in April 2020. Company is working on home monitoring for data capture.
Risks and Contingencies
The filing highlights significant risks including potential delays in clinical trials, regulatory non-approval, scientific validation failures, and the impact of the COVID-19 pandemic on enrollment rates and data collection. Forward-looking statements regarding the loan's impact on operations and trial timelines are subject to these uncertainties.
Investor Verification Checklist
- Verify the specific clinical and regulatory milestones required to trigger the disbursement of the €50 million loan tranches.
- Confirm the status of the FDA IND application and European Clinical Trial Authorization for the COVID-19 indication.
- Monitor the revised timeline for the CLI Phase III interim data readout (expected Q4 2020) and the impact of COVID-19 on data cleaning procedures.
- Review the detailed terms of the royalty payments (0.2%–2.3%) and their potential impact on future gross margins.
- Assess the Company's ability to maintain enrollment rates in ongoing Phase III trials amidst global pandemic restrictions.